Jeffrey H. Meyer

Jeffrey H. Meyer is a scientist and professor working with mood and anxiety disorders using neuroimaging at the Department of Psychiatry, University of Toronto. He is currently the head of the Neurochemical Imaging Program in Mood and Anxiety Disorders in the Brain Health Imaging Centre at the Campbell Family Mental Health Research Institute and is working as a Senior Scientist in the General and Health Systems Psychiatry Division at the Centre for Addiction and Mental Health. He has also been awarded with the Tier 1 Canada Research Chair in the Neurochemistry of Major Depression.[1]

Meyer has experience in working with positron emission tomography, including the use of [11C]DASB, [11C]harmine, [18F]FEPPA, [18F]setoperone, [11C]raclopride, [18F]SynVesT1, and [11C]SL25.1188 radioligands to examine neuropsychiatric disorders.

Areas of research

[edit]

Meyer focuses on reducing the impact of clinical depression on society through his psychiatric research. Two aspects of such research are:

In recent years, Meyer has mainly been involved in research related to neuroinflammation (e.g., markers of microglial and astroglial activation), monoamine oxidase, and markers of synaptic density. He typically conducts his research on psychiatric illness by using neuroimaging, but he also utilizes related markers when taking preclinical approaches to his research. He has also been working with early phase trials of new potential therapeutics (e.g., administering small doses of therapeutics that target pathological markers of depression in phase 0 trials), as well as creating new peripheral biomarkers that are known to be associated with certain mood disorders. He has been looking to develop natural health products that target symptoms of depression—relevant programs that he has been running include reducing the effects of depressive symptoms that are often associated with early postpartum and perimenopause.[1]

Scientific contributions

[edit]

Notable discoveries that Meyer has made in the field of psychiatric research include:

  • The creation of a dietary supplement aimed at enhancing resilience against elevated monoamine oxidase A levels during the early postpartum period. This supplement, formulated with natural antioxidants and monoamine precursors, is designed to prevent depressive moods associated with postpartum blues, a precursor to postpartum depression. Its efficacy is supported by findings from an open trial published in PNAS (2017)[2] and a randomized, double-blind placebo-controlled study published in eClinical Medicine (2024).[3] Currently, the supplement[4] is manufactured and sold in the United States, with plans for distribution in additional countries, including Canada.
  • Discovering a strong presence of neuroinflammation (i.e., gliosis) in those who are experiencing major depressive episodes[5] and that this inflammation in the brain has the potential to worsen over a longer duration if left untreated[6]
  • Discovering evidence of elevated levels of monoamine oxidase A in those who are going through early postpartum or perimenopause, as well as those who are experiencing intense emotional states associated with a higher risk for developing major depressive episodes, including: Being unable to control the consumption of alcohol, being in the early stages of nicotine withdrawal, and having a diagnosis of borderline personality disorder[7][8][9][10][11]
  • Discovering a pattern of elevated levels of monoamine oxidase A in those who are experiencing major depressive episodes[12][13]
  • Discovering a pattern of elevated levels of monoamine oxidase B in those with major depressive disorder—specifically in the prefrontal regions of the brain[14]
  • Discovering a strong presence of neuroinflammation—specifically in the implicated cortico-striatal-thalamo-cortical circuit located in the brain—in adults with obsessive-compulsive disorder[15]
  • Finding evidence that shows how selective serotonin reuptake inhibitors (SSRIS; i.e., antidepressants) produce 80% occupancy for their target site[16][17]
  • Finding a correlation between seasonal variation and serotonin transporter binding—binding is shown to increase during the winter season, compared to the summer season[18]
  • Finding patterns of elevated serotonin 2 receptor and striatal dopamine 2 receptor binding in both the prefrontal and anterior cingulate cortex—especially in those who score higher in targeted symptom clusters—in those with major depressive disorder who have remained medication-free for an extended period,[19][20] and that serotonin 2 receptor binding decreases in those who take antidepressants that raise serotonin levels[21]—this implies that it may be more effective to administer therapeutics that target specific subtypes of serotonin 2 receptors (e.g., psilocybin) prior to taking antidepressants that raise serotonin levels[1]

Awards

[edit]

Meyer has received many awards for his contributions to psychiatric research, including the following:[1]

  • The AE Bennett Award from the Society of Biological Psychiatry
  • The Distinguished Investigator Award from the Brain and Behavior Research Foundation
  • The Innovations in Psychiatry and Young Investigator Awards from the Canadian College of Neuropsychopharmacology
  • The Samarthji Lal Award from the Graham Boeckh Foundation
  • The John Dewan Prize from the Ontario Mental Health Foundation
  • The Royal College Medal Award in Medicine, for outstanding contributions to psychiatric research

References

[edit]
  1. ^ a b c d e "Dr. Jeffrey Meyer". CAMH. Retrieved 5 January 2022.
  2. ^ Dowlati, Yekta; Ravindran, Arun V.; Segal, Zindel V.; Stewart, Donna E.; Steiner, Meir; Meyer, Jeffrey H. (2017-03-28). "Selective dietary supplementation in early postpartum is associated with high resilience against depressed mood". Proceedings of the National Academy of Sciences. 114 (13): 3509–3514. doi:10.1073/pnas.1611965114. ISSN 0027-8424. PMC 5380083. PMID 28289215.
  3. ^ Meyer, Jeffrey H.; Wang, Z.; Santhirakumar, A.; Dowlati, Y.; Docteur, N.; Shoaib, A.; Sit, V. (2024). "Dietary supplement for mood symptoms in early postpartum: a double-blind randomized placebo-controlled trial". EClinicalMedicine. 71.
  4. ^ "Blues Away". Blues Away. Retrieved 18 October 2024.
  5. ^ Setiawan, Elaine; Wilson, Alan A.; Mizrahi, Romina; Rusjan, Pablo M.; Miler, Laura; Rajkowska, Grazyna; Suridjan, Ivonne; Kennedy, James L.; Rekkas, P. Vivien; Houle, Sylvain; Meyer, Jeffrey H. (2015-03-01). "Role of Translocator Protein Density, a Marker of Neuroinflammation, in the Brain During Major Depressive Episodes". JAMA Psychiatry. 72 (3): 268–275. doi:10.1001/jamapsychiatry.2014.2427. ISSN 2168-622X. PMC 4836849. PMID 25629589.
  6. ^ Setiawan, Elaine; Attwells, Sophia; Wilson, Alan A; Mizrahi, Romina; Rusjan, Pablo M; Miler, Laura; Xu, Cynthia; Sharma, Sarita; Kish, Stephen; Houle, Sylvain; Meyer, Jeffrey H (2018-04-01). "Association of translocator protein total distribution volume with duration of untreated major depressive disorder: a cross-sectional study". The Lancet Psychiatry. 5 (4): 339–347. doi:10.1016/S2215-0366(18)30048-8. PMID 29496589.
  7. ^ Sacher, Julia; Wilson, Alan A.; Houle, Sylvain; Rusjan, Pablo; Hassan, Sabrina; Bloomfield, Peter M.; Stewart, Donna E.; Meyer, Jeffrey H. (2010-05-01). "Elevated Brain Monoamine Oxidase A Binding in the Early Postpartum Period". Archives of General Psychiatry. 67 (5): 468–474. doi:10.1001/archgenpsychiatry.2010.32. ISSN 0003-990X. PMID 20439828.
  8. ^ Bacher, Ingrid (2011-08-01). "Monoamine Oxidase A Binding in the Prefrontal and Anterior Cingulate Cortices During Acute Withdrawal From Heavy Cigarette Smoking". Archives of General Psychiatry. 68 (8): 817–826. doi:10.1001/archgenpsychiatry.2011.82. ISSN 0003-990X. PMID 21810646.
  9. ^ Rekkas, Paraskevi Vivien; Wilson, Alan A.; Lee, Vivian Wai Han; Yogalingam, Priyanga; Sacher, Julia; Rusjan, Pablo; Houle, Sylvain; Stewart, Donna E.; Kolla, Nathan J.; Kish, Stephen; Chiuccariello, Lina (2014-08-01). "Greater Monoamine Oxidase A Binding in Perimenopausal Age as Measured With Carbon 11–Labeled Harmine Positron Emission Tomography". JAMA Psychiatry. 71 (8): 873–879. doi:10.1001/jamapsychiatry.2014.250. ISSN 2168-622X. PMC 4942269. PMID 24898155.
  10. ^ Matthews, Brittany A.; Kish, Stephen J.; Xu, Xin; Boileau, Isabelle; Rusjan, Pablo M.; Wilson, Alan A.; DiGiacomo, Dan; Houle, Sylvain; Meyer, Jeffrey H. (2014-05-15). "Greater Monoamine Oxidase A Binding in Alcohol Dependence". Biological Psychiatry. 75 (10): 756–764. doi:10.1016/j.biopsych.2013.10.010. PMC 4942263. PMID 24269057.
  11. ^ Kolla, Nathan J.; Chiuccariello, Lina; Wilson, Alan A.; Houle, Sylvain; Links, Paul; Bagby, R. Michael; McMain, Shelley; Kellow, Charis; Patel, Jalpa; Rekkas, Paraskevi V.; Pasricha, Suvercha (2016-01-15). "Elevated Monoamine Oxidase-A Distribution Volume in Borderline Personality Disorder Is Associated With Severity Across Mood Symptoms, Suicidality, and Cognition". Biological Psychiatry. 79 (2): 117–126. doi:10.1016/j.biopsych.2014.11.024. PMC 4942262. PMID 25698585.
  12. ^ Meyer, Jeffrey H.; Ginovart, Nathalie; Boovariwala, Anahita; Sagrati, Sandra; Hussey, Doug; Garcia, Armando; Young, Trevor; Praschak-Rieder, Nicole; Wilson, Alan A.; Houle, Sylvain (2006-11-01). "Elevated Monoamine Oxidase A Levels in the Brain: An Explanation for the Monoamine Imbalance of Major Depression". Archives of General Psychiatry. 63 (11): 1209–1216. doi:10.1001/archpsyc.63.11.1209. ISSN 0003-990X. PMID 17088501.
  13. ^ Meyer, Jeffrey H.; Wilson, Alan A.; Sagrati, Sandra; Miler, Laura; Rusjan, Pablo; Bloomfield, Peter M.; Clark, Michael; Sacher, Julia; Voineskos, Aristotle N.; Houle, Sylvain (2009-12-01). "Brain Monoamine Oxidase A Binding in Major Depressive Disorder: Relationship to Selective Serotonin Reuptake Inhibitor Treatment, Recovery, and Recurrence". Archives of General Psychiatry. 66 (12): 1304–1312. doi:10.1001/archgenpsychiatry.2009.156. ISSN 0003-990X. PMID 19996035.
  14. ^ Moriguchi, Sho; Wilson, Alan A.; Miler, Laura; Rusjan, Pablo M.; Vasdev, Neil; Kish, Stephen J.; Rajkowska, Grazyna; Wang, Junming; Bagby, Michael; Mizrahi, Romina; Varughese, Ben (2019-06-01). "Monoamine Oxidase B Total Distribution Volume in the Prefrontal Cortex of Major Depressive Disorder: An [ 11 C]SL25.1188 Positron Emission Tomography Study". JAMA Psychiatry. 76 (6): 634–641. doi:10.1001/jamapsychiatry.2019.0044. ISSN 2168-622X. PMC 6551845. PMID 30840042.
  15. ^ Attwells, Sophia; Setiawan, Elaine; Wilson, Alan A.; Rusjan, Pablo M.; Mizrahi, Romina; Miler, Laura; Xu, Cynthia; Richter, Margaret Anne; Kahn, Alan; Kish, Stephen J.; Houle, Sylvain (2017-08-01). "Inflammation in the Neurocircuitry of Obsessive-Compulsive Disorder". JAMA Psychiatry. 74 (8): 833–840. doi:10.1001/jamapsychiatry.2017.1567. ISSN 2168-622X. PMC 5710556. PMID 28636705.
  16. ^ Meyer, Jeffrey H.; Wilson, Alan A.; Ginovart, Nathalie; Goulding, Verdell; Hussey, Doug; Hood, Karen; Houle, Sylvain (2001-11-01). "Occupancy of Serotonin Transporters by Paroxetine and Citalopram During Treatment of Depression: A [11C]DASB PET Imaging Study". American Journal of Psychiatry. 158 (11): 1843–1849. doi:10.1176/appi.ajp.158.11.1843. ISSN 0002-953X. PMID 11691690.
  17. ^ Meyer, Jeffrey H.; Wilson, Alan A.; Sagrati, Sandra; Hussey, Doug; Carella, Anna; Potter, William Z.; Ginovart, Nathalie; Spencer, Edgar P.; Cheok, Andy; Houle, Sylvain (2004-05-01). "Serotonin Transporter Occupancy of Five Selective Serotonin Reuptake Inhibitors at Different Doses: An [11C]DASB Positron Emission Tomography Study". American Journal of Psychiatry. 161 (5): 826–835. doi:10.1176/appi.ajp.161.5.826. ISSN 0002-953X. PMID 15121647. S2CID 27956944.
  18. ^ Praschak-Rieder, Nicole; Willeit, Matthaeus; Wilson, Alan A.; Houle, Sylvain; Meyer, Jeffrey H. (2008-09-01). "Seasonal Variation in Human Brain Serotonin Transporter Binding". Archives of General Psychiatry. 65 (9): 1072–1078. doi:10.1001/archpsyc.65.9.1072. ISSN 0003-990X. PMID 18762593.
  19. ^ Meyer, Jeffrey H.; McMain, Shelley; Kennedy, Sidney H.; Korman, Lorne; Brown, Gregory M.; DaSilva, Jean N.; Wilson, Alan A.; Blak, Thomas; Eynan-Harvey, Rahel; Goulding, Verdell S.; Houle, Sylvain (2003-01-01). "Dysfunctional Attitudes and 5-HT 2 Receptors During Depression and Self-Harm". American Journal of Psychiatry. 160 (1): 90–99. doi:10.1176/appi.ajp.160.1.90. ISSN 0002-953X. PMID 12505806.
  20. ^ Meyer, Jeffrey H.; McNeely, Heather E.; Sagrati, Sandra; Boovariwala, Anahita; Martin, Krystle; Verhoeff, N. Paul L.G.; Wilson, Alan A.; Houle, Sylvain (2006-09-01). "Elevated Putamen D 2 Receptor Binding Potential in Major Depression With Motor Retardation: An [ 11 C]Raclopride Positron Emission Tomography Study". American Journal of Psychiatry. 163 (9): 1594–1602. doi:10.1176/ajp.2006.163.9.1594. ISSN 0002-953X. PMID 16946186.
  21. ^ Meyer, Jeffrey H.; Kapur, Shitij; Eisfeld, Beata; Brown, Gregory M.; Houle, Sylvain; DaSilva, Jean; Wilson, Alan A.; Rafi-Tari, Shahryar; Mayberg, Helen S.; Kennedy, Sidney H. (2001-01-01). "The Effect of Paroxetine on 5-HT 2A Receptors in Depression: An [ 18 F]Setoperone PET Imaging Study". American Journal of Psychiatry. 158 (1): 78–85. doi:10.1176/appi.ajp.158.1.78. ISSN 0002-953X. PMID 11136637.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Jeffrey_H._Meyer&oldid=1251947292"